Back to News
Market Impact: 0.35
IDXX Q3 Earnings & Revenues Surpass Estimates, Stock Up in Pre-Market
Source: zacks.com
Corporate EarningsCorporate Guidance & OutlookCompany FundamentalsHealthcare & Biotech
IDEXX Laboratories beat Q3 2026 earnings and revenue estimates, with diagnostic demand supporting growth and margin expansion. The company raised its 2026 revenue and earnings guidance; the article provides no specific financial figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
IDXX0.75
More News
- Stocks making the biggest moves midday: Oracle, SpaceX, Tempus AI, Rivian & more
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Marvell, Lumentum tout historic $115B deal to create ‘category leader' in AI connectivity
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear